dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Solé, Alexandra |
dc.contributor.author | Aguilar, Helena |
dc.contributor.author | Ampudia, Ana |
dc.contributor.author | Costa-Samarra, Jaume |
dc.contributor.author | Mallén-Alberdi, Maria |
dc.contributor.author | Miravitlles, Marc |
dc.date.accessioned | 2022-05-13T06:41:45Z |
dc.date.available | 2022-05-13T06:41:45Z |
dc.date.issued | 2021-11-16 |
dc.identifier.citation | Miravitlles M, Solé A, Aguilar H, Ampudia A, Costa-Samarra J, Mallén-Alberdi M, et al. Economic Impact of Low Adherence to COPD Management Guidelines in Spain. Int J Chron Obstruct Pulmon Dis. 2021 Nov 16;16:3131–43. |
dc.identifier.issn | 1178-2005 |
dc.identifier.uri | https://hdl.handle.net/11351/7526 |
dc.description | Malaltia pulmonar obstructiva crònica; Recomanacions; Tractament |
dc.description.sponsorship | This analysis has been funded by Boehringer Ingelheim Spain. Partial results were presented at the XXVII SEMG Congress (Sociedad Española de Médicos Generales y de Familia) in June 2021. |
dc.language.iso | eng |
dc.publisher | Dove Medical Press |
dc.relation.ispartofseries | International Journal of Chronic Obstructive Pulmonary Disease;16 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Pulmons - Malalties obstructives - Tractament |
dc.subject | Assistència sanitària - Cost |
dc.subject | Protocols clínics |
dc.subject.mesh | Pulmonary Disease, Chronic Obstructive |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Guideline Adherence |
dc.subject.mesh | Cost Savings |
dc.title | Economic Impact of Low Adherence to COPD Management Guidelines in Spain |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.2147/COPD.S322793 |
dc.subject.decs | enfermedad pulmonar obstructiva crónica |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | observancia de las directrices |
dc.subject.decs | ahorro de costes |
dc.relation.publishversion | https://doi.org/10.2147/COPD.S322793 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Miravitlles M] Servei de Pneumologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBER for Respiratory Diseases (CIBERES), Barcelona, Spain. [Solé A, Ampudia A] Market Access Department of Boehringer Ingelheim SA, Barcelona, Spain. [Aguilar H] Medical Department of Boehringer Ingelheim SA, Barcelona, Spain. [Costa-Samarra J, Mallén-Alberdi M] Oblikue Consulting SL, Barcelona, Spain |
dc.identifier.pmid | 34848952 |
dc.identifier.wos | 000720369300001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |